Evidence map›Paper›PMID 36128009›Full record

ArticleJournal of clinical medicine research2022

Urothelial Carcinoma With Pulmonary Tumor Thrombotic Microangiopathy After Chemotherapy for Hodgkin Lymphoma.

Naomi Shimizu, Takuro Ito, Shuji Sato, Yoshiya Sugiura, Ichiro Tatsuno

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Naomi ShimizuDepartment of Hematology, Toho University Sakura Medical Center, Chiba, Japan.ORCID https://orcid.org/0000-0001-8295-8893
Takuro ItoDepartment of Cardiology, Toho University Sakura Medical Center, Chiba, Japan.ORCID https://orcid.org/0000-0002-8369-2270
Shuji SatoDepartment of Cardiology, Toho University Sakura Medical Center, Chiba, Japan.ORCID https://orcid.org/0000-0002-6386-8670
Yoshiya SugiuraDepartment of Surgical Pathology, Toho University Sakura Medical Center, Chiba 2858741, Japan.ORCID https://orcid.org/0000-0002-0155-9645
Ichiro TatsunoCenter for Diabetes, Metabolism and Endocrinology, Toho University Sakura Medical Center, Chiba 2858741, Japan.ORCID https://orcid.org/0000-0002-7200-7952
Toho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment-related second malignancies (SMs) remain a major concern in long-term survivors of Hodgkin lymphoma (HL). In this report, the autopsy findings of a patient with HL, who was in complete remission after chemotherapy but expired of pulmonary tumor thrombotic microangiopathy (PTTM) caused by urothelial carcinoma of the renal pelvis (UCRP), were described. A 78-year-old Japanese man with a history of classical HL developed irreversible heart failure about 2.5 years after chemotherapy. The patient expired shortly after being admitted due to ineffective treatment for heart failure. However, the cause of death was not determined. The patient's autopsy findings revealed UCRP in the left kidney, as well as infiltration around the inferior vena cava and lungs, but no HL recurrence. The primary causes of mortality were respiratory and heart failure due to PTTM. Therefore, it is essential to consider the risk of SMs and search for them in patients with HL after chemotherapy.

Indexed as

ChemotherapyHodgkin lymphomaPulmonary tumor thrombotic microangiopathySecond malignancyUrothelial carcinoma

Identifiers

PMID36128009
PMCPMC9451552
OpenAlexW4293312807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.